Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. - Net Worth and Insider Trading

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Net Worth

The estimated net worth of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. is at least $326 Million dollars as of 2024-11-13. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. is the 2101 Beneficial owner of YSB Inc and owns about 48,721,760 shares of YSB Inc (HKSE:09885) stock worth over $326 Million. Details can be seen in Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. has not made any transactions after 2023-12-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. owns 1 companies in total, including YSB Inc (HKSE:09885) .

Click here to see the complete history of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.’s form 4 insider trades.

Insider Ownership Summary of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:09885	YSB Inc	2023-12-13	2101 Beneficial owner

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Latest Holdings Summary

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. currently owns a total of 1 stock. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. owns 48,721,760 shares of YSB Inc (HKSE:09885) as of December 13, 2023, with a value of $326 Million.

Latest Holdings of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:09885	YSB Inc	2023-12-13	48,721,760	6.70	326,435,792

Holding Weightings of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. has made a total of 2 transactions in YSB Inc (HKSE:09885) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in YSB Inc is the sale of 6,620,000 shares on December 13, 2023, which brought Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. around $106 Million.

Insider Trading History of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Ownership Network

Ownership Network List of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

No Data

Ownership Network Relation of Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Owned Company Details

What does YSB Inc do?

Who are the key executives at YSB Inc?

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. is the 2101 Beneficial owner of YSB Inc. Other key executives at YSB Inc include 2201 Interest of corporation controlled by you Chu Mang Yee , 2201 Interest of corporation controlled by you Meta Group Limited , and 2201 Interest of corporation controlled by you Sounda Properties Limited .

YSB Inc (HKSE:09885) Insider Trades Summary

Over the past 18 months, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. made 2 insider transaction in YSB Inc (HKSE:09885) with a net sale of 6,620,000. Other recent insider transactions involving YSB Inc (HKSE:09885) include a net sale of 16,400,000 shares made by Meta Group Limited , a net sale of 6,620,000 shares made by Fosun International Limited , and a net sale of 6,620,000 shares made by Shanghai Fosun High Technology (Group) Co., Ltd. .

In summary, during the past 3 months, insiders sold 0 shares of YSB Inc (HKSE:09885) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 73,849,200 shares of YSB Inc (HKSE:09885) were sold and 560,000,000 shares were bought by its insiders, resulting in a net purchase of 486,150,800 shares.

YSB Inc (HKSE:09885)'s detailed insider trading history can be found in Insider Trading Tracker table.

YSB Inc Insider Transactions

No Available Data

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.. Currently GuruFocus does not have mailing address information for Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd..

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.